Buscar resultados de ensayos clínicos
Histiocytosis, Non-Langerhans-Cell - 25 Studies Found
Estado | Estudiar |
Suspended |
Nombre del estudio: Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease Condición: BRAF V600E Mutation Fecha: 2014-11-01 Intervenciones:
|
Recruiting |
Nombre del estudio: Prospective Cohort for Adult Hemophagocytosis Condición: Hemophagocytic Lymphohistiocytoses Fecha: 2017-04-12 Intervenciones:
|
Recruiting |
Nombre del estudio: L-DEP as an Initial Treatment for EBV-HLH Condición: Hemophagocytic Lymphohistiocytosis Fecha: 2016-09-09 Intervenciones:
|
Recruiting |
Nombre del estudio: Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology Condición: Hemophagocytic Lymphohistiocytosis Fecha: 2016-08-06 Intervenciones: Procedure: splenectomy |
Recruiting |
Nombre del estudio: L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis Condición: Hemophagocytic Lymphohistiocytosis Fecha: 2015-12-03 Intervenciones:
|
Recruiting |
Nombre del estudio: Treatment of Familiar Lymphohistiocytosis Condición: Hemophagocytic Lymphohistiocytosis (HLH) Fecha: 2015-06-08 Intervenciones:
|
Recruiting |
Nombre del estudio: Alemtuzumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Condición: Leukemia Fecha: 2015-03-05 Intervenciones:
|
Recruiting |
Nombre del estudio: Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease Condición: Erdheim-Chester Disease Fecha: 2014-03-15 |
Recruiting |
Nombre del estudio: Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody Condición: Hemophagocytic Lymphohistiocytosis Fecha: 2013-12-23 Intervenciones: Drug: NI-0501 In the event that NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the pr |
Recruiting |
Nombre del estudio: Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) Condición: Hemophagocytic Lymphohistiocytosis Fecha: 2013-12-05 Intervenciones: Drug: tocilizumab single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of |